Albiglutide (Tanzeum)
Overview
Albiglutide is a GLP-1 receptor agonist consisting of a tandem repeat of modified human GLP-1 sequences fused to human albumin, creating a protein of approximately 73 kilodaltons with extended pharmacokinetic properties. The albumin fusion technology allows for once-weekly dosing by delaying renal clearance and protecting the peptide from enzymatic degradation. By activating GLP-1 receptors, albiglutide enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release in patients with type 2 diabetes.
Key Research Findings
Albiglutide received FDA approval in 2014 for type 2 diabetes, and the HARMONY Outcomes trial published in Lancet (2018) demonstrated cardiovascular safety with a reduction in major adverse cardiovascular events. Despite positive trial results, the manufacturer voluntarily withdrew the product from global markets in 2018 for commercial reasons unrelated to safety or efficacy concerns.
Subcutaneous injection
FDA Approved
Interested in Albiglutide (Tanzeum)?
Find a verified provider experienced with Albiglutide (Tanzeum) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Albiglutide (Tanzeum) ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.